TherapeuticsMD, Inc. Form SC 13G January 25, 2017

#### SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

## SCHEDULE 13G

(Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

#### TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

# PURSUANT TO RULE 13d-2(b)

#### THERAPEUTICSMD, INC.

(NAME OF ISSUER)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

#### 88338N107

(CUSIP Number)

December 30, 2016

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

X Rule 13d-1 (b)

Rule 13d-1 (c)

Rule 13d-1 (d)

<b>CUSIP</b> 883381		Page 1 of 3 pages
I.	Names of reporting persons JPMorgan Chase & C R.S. IDENTIFICATION NO. OF ABOVE PERSON ENTITIES ONLY)	
	CHECK THE APPROPRIATE BOX IF A MEMBER GROUP*	OF A (a) (b)
3.	SEC USE ONLY	
4.	CITIZENSHIP OR PLACE OF ORGANIZATIC Delaware	N
	IBER OF 5. SOLE VOTING POV	VER 13,000,812

Edgar Filing: TherapeuticsMD, Inc Form SC 13G				
BEN	EFICIALLY	6.	SHARED VOTING POWER	0
0	WNED BY			
	EACH	7.	SOLE DISPOSITIVE POWER	13,396,608
RE	EPORTING			
PER	SON WITH	8.	SHARED DISPOSITIVE POWER	0
9 . AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 13,396,608				
10.	CHECK BOX IF EXCLUDES CERTAIN SHAR		EGATE AMOUNT IN ROW (9)	
11.	PERCENT OF C	CLASS REPI	RESENTED BY AMOUNT IN RO	W (9)

6.8%

**TYPE OF REPORTING PERSON\*** 12.

HC

Name of Issuer: Item 1(a).

THERAPEUTICSMD, INC.

Address of Issuer's Principal Executive Offices:

Item 1(b).

6800 Broken Sound Parkway NW, Third Floor

Boca Raton, FL 33487

Item	Name of Person Filing:
2(a).	

JPMorgan Chase & Co.

Item	Address of Principal Business Office or, if None, Residence:
2(b).	

#### 270 PARK AVE

NEW YORK, NY 10017

Item	Citizenship
2(c).	

Delaware

ItemTitle of Class of Securities:2 (d) .

Common Stock, par value \$0.001 per share

Unless otherwise noted, security being reported is common stock

Item	CUSIP Number:
2(e).	

88338N107

**Item 3** If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b)

Or (c), Check Whether the Person Filing is a :

(a)

Broker or dealer registered under Section 15 of the Exchange Act;

Bank as defined in Section 3(a)(6) of the Exchange Act;

(c)

(b)

Insurance company as defined in Section 3(a)(19) of the

Exchange Act;

(d)

Investment company registered under Section 8 of the Investment

Company Act;

(e)

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with

Rule 13d-1(b)(1)(ii)(F);

(g)

#### Х

(h)

A parent holding company or control person in accordance with

Rule 13d-1(b)(1)(ii)(G);

A savings association as defined in Section 3(b) of the Federal

Deposit Insurance Act;

(i)

A church plan that is excluded from the definition of an

Investment company under Section 3(c)(14) of the Investment

Company act;

(j)

Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to X Rule 13d-1(b), check this box.

Page 2 of 3 pages

Item Ownership 4.

Provide the following information regarding the aggregate number and

#### Edgar Filing: TherapeuticsMD, Inc. - Form SC 13G

Percentage of the class of securities of issuer identified in Item 1.

(a) Amount beneficially owned:

# 13,396,608

#### Including

0 shares where there is a Right to Acquire.

(b) Percent of class:

### 6.8%

(c) Number of shares as to which such person has:

(i)	Sole power to vote or to direct the vote:	13,000,812
(ii)	Shared power to vote or to direct the vote:	0
(iii)	Sole power to dispose or to direct the disposition of:	13,396,608
(iv)	Shared power to dispose or to direct the disposition of:	0

#### Item 5. Ownership of Five Percent or Less of a Class. NOT APPLICABLE

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

( )

# **Item 6.** Ownership of More than Five Percent on Behalf of Another Person.

JPMorgan Chase & Co. is the beneficial owner of

## 13,396,608 shares of the

issuer's common stock on behalf of other persons known to have one or

more of the following:

the right to receive dividends for such securities;

the power to direct the receipt of dividends from such securities;

the right to receive the proceeds from the sale of such securities;

the right to direct the receipt of proceeds from the sale of such securities;

No such person is known to have an interest in more than 5% of the class

of securities reported herein unless such person is identified below.

**Item 7.** Identification and Classification of the Subsidiary Which Acquired the

Security being reported on by the Parent Holding Company.

This notice is filed on behalf of JPMorgan Chase & Co. and its wholly

owned Subsidiary (ies),

JPMorgan Chase Bank, National Association

J.P. Morgan Investment Management Inc.

JPMorgan Asset Management (UK) Limited

J.P. Morgan Securities LLC

**Item 8.** Identification and Classification of Members of the Group.

Not Applicable

**Item 9.** Notice of Dissolution of Group.

Not Applicable

Item Certifications 10.

By signing below I certify that, to the best of my knowledge and belief,

the securities referred to above were acquired and are held in the

ordinary course of business and were not acquired and are not held

for the purpose of or with the effect of changing or influencing

the control of the issuer of the securities and were not acquired

and are not held in connection with or as a participant in any

transaction having that purpose or effect.

Page 3 of 3 pages

# SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: January 25, 2017

JPMorgan Chase & Co.

By: /s/ Michael T. Lees

\_\_\_\_\_

Michael T. Lees

Compliance

The original statement shall be signed by each person on whose behalf the statement

is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of the filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the commission may be incorporated by reference. The name and any title of each person who signs the the statement shall be typed or printed beneath his signature.